Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**alpha-viniferin** is a naturally occurring stilbenoid trimer (specifically, a resveratrol trimer) belonging to the class of 2-arylbenzofuran flavonoids, with the molecular formula C42H30O9 and a molar mass of 678.68 g/mol[2][3][5][6][7]. It is principally isolated from several plant species, notably Caragana chamlagu, Caragana sinica, Caragana korshinskii, and is found in Vitis vinifera (grapes)[2][3][7]. Biologically, it functions as a plant metabolite, prostaglandin H2 synthase inhibitor, anti-inflammatory agent, acetylcholinesterase inhibitor, anti-oxidant, anti-arthritis agent, and anti-tumor agent[2][4][9][10][12]. Mechanistically, alpha-viniferin exhibits: - **Reversible, non-competitive inhibition of acetylcholinesterase (AChE)**, enhancing cholinergic neurotransmission and offering therapeutic potential for neurodegenerative diseases such as Alzheimer's disease[1][2][4]. - **Dose-dependent inhibition of cyclooxygenase (COX) activity**, implicating anti-inflammatory and anti-tumor effects[4][11]. - **Anti-angiogenic activity** by inhibiting endothelial cell proliferation and migration (via VEGFR-2/p70 S6 kinase pathway), potentially relevant in atherosclerosis and cancer[1]. Other reported activities include inhibition of matrix metalloproteinase-2, suppression of STAT-1-inducible inflammatory gene expression (in IFN-γ-stimulated macrophages via ERK/STAT-1 pathway), and modulation of retinoblastoma protein phosphorylation[1][4][11]. alpha-viniferin is investigated for **anti-tubercular activity**[10], neuroprotective effects, and potential biomarker of grape and wine consumption[3]. Bioavailability is low (~4.2%) after oral administration in animal models[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-viniferin.